BioLineRx Net Receivables from 2010 to 2025

BLRX Stock  USD 3.78  0.02  0.53%   
BioLineRx Net Receivables yearly trend continues to be fairly stable with very little volatility. Net Receivables is likely to outpace its year average in 2025. During the period from 2010 to 2025, BioLineRx Net Receivables regression line of annual values had r-squared of  0.21 and arithmetic mean of  1,026,894. View All Fundamentals
 
Net Receivables  
First Reported
2009-12-31
Previous Quarter
1.9 M
Current Value
281 K
Quarterly Volatility
5.2 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check BioLineRx financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioLineRx's main balance sheet or income statement drivers, such as Depreciation And Amortization of 4.3 M, Gross Profit of 20.7 M or Other Operating Expenses of 29.6 M, as well as many indicators such as Price To Sales Ratio of 0.7, Dividend Yield of 0.0 or PTB Ratio of 1.81. BioLineRx financial statements analysis is a perfect complement when working with BioLineRx Valuation or Volatility modules.
  
Build AI portfolio with BioLineRx Stock
Check out the analysis of BioLineRx Correlation against competitors.
For more information on how to buy BioLineRx Stock please use our How to Invest in BioLineRx guide.

Latest BioLineRx's Net Receivables Growth Pattern

Below is the plot of the Net Receivables of BioLineRx over the last few years. It is BioLineRx's Net Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BioLineRx's overall financial position and show how it may be relating to other accounts over time.
Net Receivables10 Years Trend
Slightly volatile
   Net Receivables   
       Timeline  

BioLineRx Net Receivables Regression Statistics

Arithmetic Mean1,026,894
Geometric Mean615,724
Coefficient Of Variation118.19
Mean Deviation834,052
Median613,000
Standard Deviation1,213,706
Sample Variance1.5T
Range3.9M
R-Value0.46
Mean Square Error1.2T
R-Squared0.21
Significance0.07
Slope117,555
Total Sum of Squares22.1T

BioLineRx Net Receivables History

20254.1 M
20243.9 M
2023708 K
2022721 K
2021142 K
2020141 K
2019613 K

About BioLineRx Financial Statements

BioLineRx investors use historical fundamental indicators, such as BioLineRx's Net Receivables, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in BioLineRx. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Receivables3.9 M4.1 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for BioLineRx Stock Analysis

When running BioLineRx's price analysis, check to measure BioLineRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLineRx is operating at the current time. Most of BioLineRx's value examination focuses on studying past and present price action to predict the probability of BioLineRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLineRx's price. Additionally, you may evaluate how the addition of BioLineRx to your portfolios can decrease your overall portfolio volatility.